



TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Notice of Full Year results and Ox-1 presentation

Alderley Park, 23 May 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, announces that the Company's full year results for the year to 31 March 2025 will be released on Tuesday, 3 June 2025. A live presentation of the results will be provided at 1pm BST that day via [Investor Meet Company](#) by Dr Huw Jones, CEO, Toni Hänninen, CFO and Dr Alastair Smith, Chair.

Post-results, on 11 June 2025, the Company will be hosting a separate webinar for investors at 11.30am BST, to provide an in-depth look at the Ox-1 addiction programme. The session will be led by TheraCryf's CBO, Dr Helen Kuhlman, together with neuroscientist and consultant to the Company, Dr Fraser Murray. Access to the session will also be via the Investor Meet Company platform.

Both presentations will be open to all existing and potential shareholders. Questions can be submitted up to 24 hours prior to either event via the Investor Meet Company dashboard or during the live presentations. Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited. New registrants can sign up to Investor Meet Company [HERE](#).

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090
enquiries@theracryf.com

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

+44 (0)20 3657 0050

Cavendish Capital Markets (NOMAD & Joint Broker)

Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 (0)20 7220 0500

Vigo Consulting

Rozi Morris

+44 (0)20 7390 0231
theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma** and neurodevelopmental disorders [**orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORPKNBKABKKAPB